FDA Accepts First Biosimilar Application From Sandoz
Novartis AG unit Sandoz Inc. announced Thursday that the U.S. Food and Drug Administration is reviewing its request to market a biosimilar version of Amgen Inc.'s Neupogen, a milestone that marks...To view the full article, register now.
Already a subscriber? Click here to view full article